Company: PHAT
Filing Date: 2025-10-27
Form Type: 8-K
Source: 0001193125-25-250611
Chunk: 0

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-10-27
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01      Other Events.  

On October 25, 2025, Phathom Pharmaceuticals, Inc. (“ Phathom” or the “ Company”) announced that results of additional analyses from its pivotal Phase 3 pHalcon-NERD-301trial evaluating VOQUEZNA®(vonoprazan) tablets in patients withNon-ErosiveReflux Disease (“ NERD”) have been published in the American Journal of Gastroenterology. The article, titled“ VonoprazanImproves Nocturnal Gastroesophageal Reflux Symptoms in Non-Erosive”, underscores the significant burden of nighttime GERD symptoms and the potential role of VOQUEZNA in addressing this aspect of the disease.